Appetite Or Satiation Affecting Patents (Class 514/4.9)
-
Publication number: 20140072557Abstract: A medicinal agent for suppressing or preventing the metastasis of a malignant tumor, the agent comprising, as an active ingredient, at least one kind of vascular endothelial intracellular cGMP enhancer.Type: ApplicationFiled: February 27, 2012Publication date: March 13, 2014Applicants: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, DAIICHI SANKYO COMPANY, LIMITED, OSAKA UNIVERSITYInventors: Kenji Kangawa, Hiroshi Hosada, Takashi Nojiri, Meinoshin Okumura
-
Publication number: 20140057838Abstract: Diseases including diabetes, metabolic syndrome, and obesity or obesity-related diseases are due to impairment in glucose metabolism. The skeleton has been shown to regulate energy metabolism and play a role in glucose metabolism. The present invention relates to methods for treating or preventing diseases such as diabetes, metabolic syndrome, and obesity or obesity-related by administering a therapeutically effective amount of osteoblast-expressed Lcn-2 or a biologically active fragment.Type: ApplicationFiled: April 11, 2012Publication date: February 27, 2014Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventor: Stavroula Kousteni
-
Publication number: 20140005105Abstract: The present invention provides pladin (plasma anti-diabetic nucb2 peptide) polypeptide and functional equivalent thereof that are useful for treating diabetes. The present invention provides a method of treating diabetes by administering to a subject nesfatin-1, pladin, or a functional equivalent thereof. The present invention also provides a method of treating diabetes by administering to subject plasmin inhibitors.Type: ApplicationFiled: August 28, 2013Publication date: January 2, 2014Applicant: Landing Biotech, Inc.Inventor: Jian-ning LIU
-
Publication number: 20130345123Abstract: The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein A is a five to eight membered monocyclic or a nine to twelve membered bicyclic heterocyclic ring, as further defined herein; Y is S, CH2, or CH; Z is CH or N; R7 and R9 are hydrogen or (C1-C6)alkyl; R2 is (C1-C6)alkoxy, OH, CN, (C1-C6)alkyl, halogen, or CF3; r and s are 0, 1, or 2; and R1 and R3 are as further defined herein. These compounds are agonists, partial agonists and/or modulators of the NPY4 receptor and may be used for the treatment and prophylaxis of obesity, food intake, and other diseases and conditions modulated by the NPY4 receptor.Type: ApplicationFiled: March 13, 2012Publication date: December 26, 2013Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Chongqing Sun, William R. Ewing, Scott A. Bolton, Zhengxiang Gu, Yanting Huang, Natesan Murugesan, Yeheng Zhu
-
Publication number: 20130336893Abstract: The present invention relates to exendin-4 peptide analogues and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.Type: ApplicationFiled: June 13, 2013Publication date: December 19, 2013Applicant: SANOFIInventors: Torsten HAACK, Andreas EVERS, Michael WAGNER, Bernd HENKEL, Siegfried STENGELIN
-
Publication number: 20130331315Abstract: The present invention provides protein hydrolysate compositions having enhanced cholecystokinin (CCK) and/or giuoagon-like peptide-1 (GLP-1) releasing activity and food forms incorporating the protein hydrolysate compositions, which can be used to promote satiety.Type: ApplicationFiled: February 23, 2012Publication date: December 12, 2013Applicant: Solae, LLCInventors: Elaine S. Krul, Barry Tulk, Mary K. Pawlik, Jason F. Lombardi
-
Publication number: 20130324462Abstract: The use of flagellin and flagellin related polypeptides for reducing cancer treatment side effects in mammals is described.Type: ApplicationFiled: March 26, 2013Publication date: December 5, 2013Inventors: Andrei V. Gudkov, Vadim Krivokrysenko, Lyudmila Burdelya
-
Publication number: 20130324461Abstract: The invention includes methods of treating, preventing, or limiting obesity or weight gain, or reducing or suppressing appetite, by the administration of A2A adenosine receptor pathway agonists. The A2AR pathway agonists may be administered in conjunction with a therapeutic agent having a side effect of weight gain, in order to prevent or limit that weight gain. In some instances, the A2AR pathway agonist is administered as a sleeping pill, and in other instances the A2AR pathway agonist is administered in a non-drowsy formulation.Type: ApplicationFiled: August 26, 2011Publication date: December 5, 2013Inventors: Michail V. Sitkovsky, Akio Ohta
-
Patent number: 8598120Abstract: The present invention relates to novel compounds having a function of a peptide in the amylin family, related nucleic acids, expression constructs, host cells, and processes production of the compounds. The compounds of the invention include one or more amino acid sequence modifications. In addition, methods and compositions are disclosed to treat and prevent metabolic disorders such as obesity, diabetes, and increased cardiovascular risk.Type: GrantFiled: February 1, 2012Date of Patent: December 3, 2013Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Christopher J. Soares, Michael R. Hanley, Diana Y. Lewis, David G. Parkes, Carolyn M. Jodka, Kathryn S. Prickett, Soumitra S. Ghosh, Christine M. Mack, Qing Lin
-
Publication number: 20130296232Abstract: The present invention relates to a composition comprising a tryptophan-containing peptide and having a Trp/LNAA ratio of more than 0.1 for decreasing eating or appetite during or after stress.Type: ApplicationFiled: September 28, 2011Publication date: November 7, 2013Applicant: DSM IP ASSETS B.V.Inventors: Cindy Gerhardt, Joris Kloek, Rob Markus
-
Publication number: 20130296231Abstract: Charged nutritive proteins are provided. In some embodiments the nutritive proteins an aqueous solubility of at least 12.5 g/L at pH 7. In some embodiments the nutritive proteins an aqueous solubility of at least 50 g/L at pH 7. In some embodiments the nutritive proteins an aqueous solubility of at least 100 g/L at pH 7.Type: ApplicationFiled: March 15, 2013Publication date: November 7, 2013Inventors: David Arthur Berry, Brett Adam Boghigian, Nathaniel W. Silver, Geoffrey von Maltzahn
-
Patent number: 8575097Abstract: The invention provides a novel Exendin variant and the Exendin variant conjugate conjugating polymer thereon, the pharmaceutical composition comprising them and use of them for treating diseases such as reducing blood glucose, treating diabetes, especially Type II diabetes. The invention also provides the use of Exendin conjugate for lowering body weight.Type: GrantFiled: April 23, 2010Date of Patent: November 5, 2013Assignee: Pegbio Co., Ltd.Inventors: Michael M. Xu, Yongxiang Wang, Yinghui Zhang, Xiaosu Luo, Nian Gong, Lijie Zhang, Xiangjun Zhou
-
Patent number: 8557765Abstract: Novel spatially-defined macrocyclic compounds incorporating peptide bond surrogates are disclosed. Libraries of these macrocycles are then used to select one or more macrocycle species that exhibit a specific interaction with a particular biological target. In particular, compounds according to the invention are disclosed as agonists or antagonists of a mammalian motilin receptor and a mammalian ghrelin receptor.Type: GrantFiled: May 26, 2009Date of Patent: October 15, 2013Assignee: Tranzyme Pharma Inc.Inventors: Pierre Deslongchamps, Yves Dory, Luc Ouellet, Gérald Villeneuve, Mahesh Ramaseshan, Daniel Fortin, Mark L. Peterson, Hamid R. Hoveyda, Sylvie Beaubien, Éric Marsault, Graeme L. Fraser
-
Publication number: 20130261051Abstract: The present invention relates to methods for treatment of a condition or disease where administration of insulin will be of benefit, comprising administering, to a patient in need thereof, effective dosages of an insulin, insulin analogue or derivative thereof, which exhibits a prolonged profile of action, wherein said dosages are administered at intervals of varying length.Type: ApplicationFiled: October 27, 2011Publication date: October 3, 2013Inventor: Thue Johansen
-
Patent number: 8541368Abstract: The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of said glucagon peptides to patients in need thereof, and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.Type: GrantFiled: September 21, 2012Date of Patent: September 24, 2013Assignee: Novo Nordisk A/SInventors: Jesper F. Lau, Thomas Kruse, Henning Thoegersen, Ulrich Sensfuss, Peter Kresten Nielsen
-
Publication number: 20130231278Abstract: The present invention relates to a process to produce a composition comprising water-soluble peptides and having a Trp/LNAA ratio of more than 0.15, which comprises hydrolyzing lysozyme, preferably hen eggs lysozyme, to prepare a hydrolysate having a DH of between 5 and 45.Type: ApplicationFiled: October 31, 2012Publication date: September 5, 2013Applicant: DSM IP Assets B.V.Inventors: Andre Leonardus De Roos, Luppo Edens, Rudolf Franciscus Van Beckhoven, Alexander Lucia Leonardus Duchateau, Joris Kloek
-
Publication number: 20130225486Abstract: The present invention relates to the field of nutrition; in particular to the prevention and/or treatment of malnutrition. One embodiment of the present invention relates to a nutritional composition enriched in cysteine for use in the treatment and/or prevention of malnutrition and disorders related thereto. Such a composition may in particular, but not exclusively, be useful for the elderly population.Type: ApplicationFiled: October 19, 2011Publication date: August 29, 2013Inventors: Denis Breuille, Isabelle Papet, Karine Vidal
-
Publication number: 20130225485Abstract: Compositions and methods for preventing, treating or controlling conditions or disorders associated with obesity, diet and nutrition are provided. The methods provided generally involve the administration of an Amylin or an Amylin agonist to a subject in order to prevent, treat or control conditions or disorders associated with obesity, diet and nutrition.Type: ApplicationFiled: September 28, 2012Publication date: August 29, 2013Applicant: Amylin Pharmaceuticals, LLCInventor: Amylin Pharmaceuticals, LLC
-
Patent number: 8501685Abstract: A process for producing a peptide product having cholecystokinin secretion promoting effect, said process comprising hydrolyzing soybean residues with one or more proteases so that the peptide product having cholecystokinin secretion promoting effect is obtained. Also disclosed is the composition containing the peptide product and the use thereof.Type: GrantFiled: October 5, 2011Date of Patent: August 6, 2013Assignee: Food Industry Research and Development InstituteInventors: Yi-Hong Chen, Yu-Hui Liu, Chu-Chin Chen, Shiao-Cheng Chuang, Hsiang-Ling Lai, Chien-Ti Chang, Ming-Yu Hung, Su-Er Liou, Fu-Ning Chien
-
Publication number: 20130177647Abstract: Various embodiments of the invention disclosed herein include methods of inducing satiety a mammal in need thereof. Also disclosed are methods of inducing satiety in an obese mammal. Additionally disclose are method of suppressing appetite in a mammal in need thereof. Further disclosed are methods of treating obesity. The methods described herein involve the administration of serotonin, a serotonin agonist or a serotonin re-uptake inhibitor to the mammal.Type: ApplicationFiled: March 1, 2013Publication date: July 11, 2013Applicant: CEDARS-SINAI MEDICAL CENTERInventor: CEDARS-SINAI MEDICAL CENTER
-
Patent number: 8481484Abstract: A novel cyclic heptapeptide that is useful as a preadipocyte differentiation-inhibitory agent or an adipocyte fat accumulation-inhibitory agent, and the use of such agents, are provided. A novel cyclic heptapeptide represented by the following formula is provided. wherein R is CH3, CH2CH(CH3)2, CH2OCH2C6H5, CH(OH)CH3, or CH2OH.Type: GrantFiled: June 6, 2008Date of Patent: July 9, 2013Assignee: National University Corporation Nagoya UniversityInventors: Daisuke Uemura, Kenichiro Shimokawa, Yoshiaki Iwase, Kaoru Yamada
-
Publication number: 20130157928Abstract: The present invention relates to nociceptin peptide mimetics that have ?-helical structures and bind to and modulate the opioid receptor-like-1 (ORL-1) receptor. The peptide mimetics are constrained cyclic nociceptin analogues which have either agonist or antagonist activity. Pharmaceutical compositions comprising the nociceptin peptide mimetics and methods of treating or preventing a disease or condition ameliorated by modulating the ORL-1 receptor are also described.Type: ApplicationFiled: June 7, 2011Publication date: June 20, 2013Inventors: David Fairlie, Rosemary Sharon Harrison, Nicholas Evan Shepherd
-
Publication number: 20130137629Abstract: Various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis can be treated with a compound selected from an incretin mimetic and a dipeptidyl peptidase IV inhibitor in combination with a Compound of Formula I or a pharmaceutically acceptable salt thereof Three of R1, R2, R3, R4 and R5 are hydrogen and the remainder are independently selected from the group consisting of hydrogen, halo, hydroxy, methyl, ethyl, perfluoromethyl, methoxy, ethoxy, and perfluoromethoxy; and m is 0, 2 or 4. R6 is hydrogen, O or hydroxy, and X is —OR7, wherein R7 is hydrogen or alkyl having from 1 to 3 carbon atoms; or R6 is hydrogen, and X is —NR8R9, wherein R8 is hydrogen or hydroxy and R9 is hydrogen, methyl or ethyl. When X is —NR8R9, hydroxy none of R1, R2, R3, R4 and R5 is hydroxy.Type: ApplicationFiled: January 24, 2013Publication date: May 30, 2013Applicant: WELLSTAT THERAPEUTICS CORPORATIONInventor: WELLSTAT THERAPEUTICS CORPORATION
-
Patent number: 8431532Abstract: Methods of treatment using Fzd8 extracellular domains (ECDs), Fzd8 ECD fusion molecules, and/or antibodies that bind Fzd8 are provided. Such methods include, but are not limited to, methods of treating obesity and obesity-related conditions. Fzd8 ECDs and Fzd8 ECD fusion molecules are also provided. Polypeptide and polynucleotide sequences, vectors, host cells, and compositions comprising or encoding such molecules are provided. Methods of making and using Fzd8 ECDs, Fzd8 ECD fusion molecules, and antibodies that bind Fzd8 are also provided.Type: GrantFiled: June 27, 2011Date of Patent: April 30, 2013Assignee: Five Prime Therepeutics, Inc.Inventors: Thomas Brennan, Ernestine Lee, Steven Smith
-
Publication number: 20130089545Abstract: The invention provides a peptide comprising the amino acid sequence given below, together with uses of the peptide and methods associated therewith. The peptide finds particular use as an appetite suppressant and in the treatment of obesity.Type: ApplicationFiled: September 22, 2011Publication date: April 11, 2013Inventor: Stephen Robert Bloom
-
Patent number: 8415296Abstract: The present invention provides Oxyntomodulin peptide analogues useful in the treatment of diabetes and/or obesity.Type: GrantFiled: December 15, 2010Date of Patent: April 9, 2013Assignee: Eli Lilly and CompanyInventors: Jorge Alsina-Fernandez, Wayne David Kohn
-
Publication number: 20130072445Abstract: The present invention relates to the use of a mutant CRP molecule in which tyrosine 175 is replaced by leucine (Y175L CRP) or the leucine 176 is replaced by glutamic acid (L176E CRP) for the treatment of various disease states and conditions associated with SLE, including lupus of the skin (discoid), systemic lupus of the joints, lungs and kidneys, hematological conditions including hemolytic anemia and low lymphocyte counts, lymphadenopathy and CNS effects, including memory loss, seizures and psychosis, among numerous others as otherwise disclosed herein. In another aspect of the invention, the reduction in the likelihood that a patient who is at risk for an outbreak of a disease state or condition associated with SLE will have an outbreak is an additional aspect of the present invention. The present invention relates to the use of mutant Y175L CRP or L176E CRP in the treatment of a number of disease states or conditions that occur secondary to systemic lupus SLE.Type: ApplicationFiled: June 2, 2009Publication date: March 21, 2013Inventors: Terry W. Du Clos, Carolyn Mold
-
Publication number: 20130065816Abstract: This invention relates to novel analogs of pituitary adenylate cyclase-activating polypeptide (PACAP), which are agonists for the PACAP/vasoactive intestinal peptide (VIP) receptors: PAC1, VPAC1 and VPAC2 receptors. These PACAP analogs can be used as prophylactic/therapeutic agents for a wide range of medical disorders, including (but not limited to) cancer and autoimmune disease. These PACAP analogs can be coupled to suitable radionuclides and used in the localization, diagnosis and treatment of disseminated cancers and metastatic tumors, or coupled to small molecule therapeutics and used as vectors for targeted drug delivery. This invention also provides pharmaceutical compositions of one or more PACAP-like compounds of the invention either alone or in combination with one or more other prophylactic/therapeutic agents.Type: ApplicationFiled: November 2, 2010Publication date: March 14, 2013Applicant: The Administrators of the Tulane Educational FundInventors: David H. Coy, Jerome L. Maderdrut, Min Li
-
Publication number: 20130053304Abstract: Provided is a glucagon-like peptide-1 (GLP-1) analogue shown as the following formula, wherein X is selected from glycine and glycinamide. The GLP-1 analogue has a non-proteogenic amino acid residue in position 8 relative to the sequence GLP-1, and is acylated with a moiety comprising two acidic groups to the lysine residue in position 26. The GLP-1 analogue is resistant to dipeptidyl peptidase IV so as to have an extended half-life in vivo. Also provided is a use of the GLP-1 analogue in conquering blood sugar.Type: ApplicationFiled: April 29, 2011Publication date: February 28, 2013Inventors: Yinxiang Wang, Fenlai Tan, Shaojing Hu, Xiangdong Zhao, Cunbo Ma, Yanping Wang, Xiaoyan Shen, Lieming Ding, Yunyan Hu, Hong Cao, Wei Long
-
Publication number: 20130045915Abstract: The present disclosure relates to a weight-loss composition including protein and fat and methods of use. The weight loss composition is substantially free of carbohydrates. The composition induces body weight loss when administered to a subject as the only source of nutrition for at least 12 hours.Type: ApplicationFiled: August 20, 2012Publication date: February 21, 2013Applicant: EUROPEAN KETOGENIC WEIGHT LOSS CLINICS LLCInventor: Oliver R. DI PIETRO
-
Patent number: 8377877Abstract: A nutritional intervention composition for reducing post-prandial blood glucose levels in humans, including between about 0.1 mg and about 500 mg of a proteinase inhibitor that is administered prior to the meal. The composition is effective for treating or ameliorating the effects of hyperglycemia and Type II diabetes. The composition also is effective in combating obesity. The proteinase inhibitor is preferably isolated from plant material, such as potatoes, soy, and beans. Potato proteinase inhibitor II and soybean Bowman-Birk inhibitor are included in the group of effective proteinase inhibitors.Type: GrantFiled: April 30, 2003Date of Patent: February 19, 2013Assignee: Kemin Foods, L.C.Inventors: Rodney Ausich, Jerry Newman, Zoriada DeFeitas, Andrew Shao, Fayad Z. Sheabar
-
Patent number: 8362297Abstract: The present disclosure relates to high protein dietary supplements for treating various symptoms and diseases associated with protein deficiency including weight gain, obesity, catabolic diseases, fibromyalgia, anxiety reactions, posttraumatic stress and chronic fatigue syndrome. Embodiments of dietary supplements comprise combinations of proteins, essential and semi-essential amino acids including L-Lysine, L-Arginine, and/or L-Histidine.Type: GrantFiled: June 20, 2011Date of Patent: January 29, 2013Inventor: George Scheele
-
Publication number: 20130023464Abstract: Peptide analogues of PYY, compositions comprising said analogues and methods of using said analogues for the treatment and prevention of metabolic disorders, for example disorders of energy metabolism such as diabetes and obesity, and for a reduction in appetite, reduction in food intake or reduction of calorie intake in a subject.Type: ApplicationFiled: January 27, 2011Publication date: January 24, 2013Inventor: Stephen Robert Bloom
-
Publication number: 20130023465Abstract: Use of Human Chorionic Gonadotropin (hCG) by oral-sublingual or injectable route for the treatment of several food disorders, as an appetite-suppressant agent, food compulsiveness as well as all of those pathologies related to hunger and/or appetite modifications, including overweight, obesity, anorexia, bulimia, emotional hyperphagia, without excluding other pathologies associated to overingestion or reduced ingestion. It also includes its use for the treatment of behavior disorders associated with an increased ingestion, either behavior disorders, neurosis, borderline personality disorders or psychosis, without excluding other psychosomatic disorders.Type: ApplicationFiled: September 17, 2012Publication date: January 24, 2013Inventor: DANIEL OSCAR BELLUSCIO
-
Publication number: 20130012432Abstract: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.Type: ApplicationFiled: February 28, 2011Publication date: January 10, 2013Applicant: Novo Nordisk A/SInventors: Kilian Waldemar Conde-Frieboes, Jane Spetzler, Ulrich Sensfuss, Birgitte Schjellerup Wulff, Henning Thoegersen, Jens Christian Norrild
-
Patent number: 8349797Abstract: The present invention is directed to a compound according to formula, (R2R3)-B1-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-A11-A12-A13-B2-B3-R1, that act as ligands for one or more of the melanocortin receptors, the pharmaceutically-acceptable salts thereof, to methods of using such peptides to treat mammals and to pharmaceutical compositions useful therefore comprising said peptides.Type: GrantFiled: July 10, 2006Date of Patent: January 8, 2013Assignee: IPSEN Pharma S.A.S.Inventors: Zheng Xin Dong, Jacques-Pierre Moreau
-
Publication number: 20130004601Abstract: A dietary supplement for regulating the appetite of an individual is described. The dietary supplement comprises at least one mechanical satiety regulator, and at least one chemical satiety inducer, and may additionally comprise at least one thermogen, and/or at least one side effect remover. The dietary supplement induces satiety based on a combination of occupying part of the volume of the stomach, inducing sending signals to the brain in respect of satiety. Furthermore the dietary supplement may maintain or increase metabolism and reduce side effects such as the amount of produced flatulence. The dietary supplement may comprise fibre, whey, plant parts from plants e.g. of the genus Capsicum and plant parts from a species e.g. of the genus Mentha.Type: ApplicationFiled: November 26, 2010Publication date: January 3, 2013Inventors: Soren Vedel Saaby Nielsen, Claude Teisen-Simony
-
Patent number: 8318664Abstract: A method for treating obesity and more particularly a method for treating diet-induced obesity in a subject comprising administering to said subject an isolated unacylated ghrelin peptide as set forth in SEQ ID NO: 1, a fragment thereof or a cyclic fragment thereof such as a cyclic unacylated ghrelin fragment. The method being achievable without affecting the food intake of the subject.Type: GrantFiled: April 29, 2011Date of Patent: November 27, 2012Assignee: Alize Pharma SASInventor: Aart Jan Van Der Lely
-
Patent number: 8299022Abstract: The invention comprises peptidyl analogs of ghrelin having greater stability which are active at the GHS receptor according to formulae depicted below: (R2)-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-R1 wherein the definitions of A1 to A28, R1 and R2 are provided for in the specification, with the exception that the N-terminal amino acid must be selected from the group consisting of Inp, 1-Apc and 4-Apc, the pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising an effective amount of said compound together with therapeutic and non-therapeutic uses thereof.Type: GrantFiled: September 24, 2007Date of Patent: October 30, 2012Assignee: IPSEN Pharma S.A.S.Inventor: Zheng Xin Dong
-
Patent number: 8283311Abstract: A safe and widely-applicable food intake regulator can be provided by using at least one peptide selected from the group consisting of a fish or mammalian melanin-concentrating hormone (MCH) and enzymatic digests thereof, which have the activity to suppress food intake.Type: GrantFiled: March 3, 2009Date of Patent: October 9, 2012Assignee: Maruha Nichiro Foods, Inc.Inventors: Hiroyuki Enari, Motohiko Tada, Yoshinori Takahashi, Masataka Kawarasaki
-
Patent number: 8278267Abstract: Compositions and methods for preventing, treating or controlling conditions or disorders associated with obesity, diet and nutrition are provided. The methods provided generally involve the administration of an Amylin or an Amylin agonist to a subject in order to prevent, treat or control conditions or disorders associated with obesity, diet and nutrition.Type: GrantFiled: December 9, 2010Date of Patent: October 2, 2012Assignee: Amylin Pharmaceuticals, LLCInventors: Christian Weyer, Kevin D. Laugero, Christine M. Mack, David G. Parkes
-
Patent number: 8268779Abstract: Modified oxyntomodulin derivatives. Such derivatives can be used for the treatment of metabolic diseases such as diabetes and obesity.Type: GrantFiled: March 21, 2011Date of Patent: September 18, 2012Assignee: Merck Sharp & Dohme Corp.Inventors: Ranabir Sinha Roy, Elisabetta Bianchi, Antonello Pessi, Paolo Ingallinella, Donald J. Marsh, George J. Eiermann, Yingjun Mu, Yun-Ping Zhou
-
Patent number: 8258094Abstract: The invention comprises peptidyl analogs according to formulae (I) or (II) as depicted below: (R2R3)-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13- A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25- A-26-A27-A28-R1 wherein the definitions of A1 to A28 and R1 to R3 are provided for in the specification for each of formulae (I) and (II), pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising an effective amount of a compound of formula (I), that possess agonist or antagonist ghrelin activity, along with therapeutic and non-therapeutic uses thereof.Type: GrantFiled: March 28, 2008Date of Patent: September 4, 2012Assignee: IPSEN Pharma S.A.S.Inventors: Zheng Xin Dong, Michael DeWitt Culler, Yeelana Shen, Jeanne Mary Comstock
-
Publication number: 20120219616Abstract: The invention enables management of mammalian disease related to decreased energy production in the mitochondria by a combination of liposomal reduced glutathione and 1-arginine. For individuals whose inability to lose weight is related to inefficiency of the biochemical pathways facilitating mitochondrial function and energy production, the invention proposes to assist in weight loss by improving the inefficient production of energy by the respiratory transport chain of mitochondria. The invention is useful for the management of the metabolic syndrome, a group of metabolic factors associated with an increased risk of vascular disease problems. The invention is also useful for the resolution of fatigue that accompanies both weight gain and illnesses. The ability of the invention to increase the production of the biochemical agmatine in the central nervous system as well as generally in the body is part of the benefit of the combination of liposomal reduced glutathione and 1-arginine.Type: ApplicationFiled: February 8, 2012Publication date: August 30, 2012Applicant: YOUR ENERGY SYSTEMS, LLCInventors: F. Timothy Guilford, Brian C. Keller
-
Patent number: 8227414Abstract: Peptide analogs of nociceptin/orphanin FQ, compositions thereof, and their use in treatment of disorders and dysfunctions related to activation or blocking of NOP receptors are described.Type: GrantFiled: February 15, 2006Date of Patent: July 24, 2012Assignee: UFPEPTIDES S.R.L.Inventors: Remo Guerrini, Severo Salvadori, Girolamo Calo', Domenico Regoli
-
Patent number: 8217139Abstract: The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like.Type: GrantFiled: November 14, 2011Date of Patent: July 10, 2012Assignee: Unigene Laboratories, Inc.Inventors: Nozer M. Mehta, Amy Sturmer, William Stern, James P. Gilligan
-
Publication number: 20120172294Abstract: The invention provides (i) a method of treating metabolic syndrome in an animal, (ii) a method of suppressing the appetite of an animal, (iii) a method of treating obesity in an animal, (iv) a method of reducing the weight of an animal in need thereof, (v) a method of reducing a blood lipid level in an animal in need thereof, (vi) a method of treating non-alcoholic steatohepatitis in an animal, and (vii) a method of inhibiting adipogenesis. The methods comprise administering an effective amount of an active ingredient, wherein the active ingredient comprises a diketopiperazine, a prodrug of a diketopiperazine or a pharmaceutically-acceptable salt of either of them to the animal. The invention also provides a kit comprising a container holding a diketopiperazine, a prodrug of a diketopiperazine or a pharmaceutically-acceptable salt of either of them; and instructions for administration. The diketopiperazines have the formula given in the application.Type: ApplicationFiled: September 7, 2011Publication date: July 5, 2012Applicant: DMI ACQUISITION CORP.Inventor: David Bar-Or
-
Patent number: 8202836Abstract: The present invention relates to compounds of formula (I); variants or derivatives thereof, or salts or solvates thereof. The present invention also relates to the use of such compounds to control appetite, feeding, food intake, energy expenditure and calorie intake, particularly in the treatment of obesity.Type: GrantFiled: March 9, 2006Date of Patent: June 19, 2012Assignee: Imperial Innovations LimitedInventors: Stanley Moore, Mohammad Ghatei, Stephen Robert Bloom
-
Publication number: 20120149635Abstract: The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like.Type: ApplicationFiled: November 14, 2011Publication date: June 14, 2012Applicant: Unigene Laboratories Inc.Inventors: Nozer M. Mehta, Amy Sturmer, William Stern, James P. Gilligan
-
Publication number: 20120141416Abstract: The present invention relates to multimeric (e.g., dimeric, trimeric) forms of peptide vectors that are capable of crossing the blood-brain barrier (BBB) or efficiently entering particular cell types. These multimeric peptide vectors, when conjugated to agents (e.g., therapeutic agents) are capable of transporting the agents across the BBB or into particular cell types. These compounds are therefore particularly useful in the treatment of neurological diseases.Type: ApplicationFiled: June 30, 2010Publication date: June 7, 2012Applicant: Angiochem Inc.Inventors: Michel Demeule, Christian Che, Carine Thiot